News & Updates

New drug applications approved by US FDA as of 1-15 May 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

High cardiorespiratory fitness during adolescence appears to provide protection against cancer development and death in late adulthood, suggests a study. This finding is consistent in sibling comparisons.

A recent study claims that almost half of the patients treated for skin cancer will again develop the disease within 2 years of the first incidence.

This article will summarize the latest developments in the first-line management of advanced EGFRm NSCLC and highlight key consideration factors.

A multinational phase I study led by the Chinese University of Hong Kong (CUHK) reports an overall objective response rate (ORR) of >70 percent in advanced solid KRAS^G12C-mutant tumours treated with D3S-001, a next-generation KRAS^G12C inhibitor developed in mainland China.

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs), as opposed to insulin or metformin, provides a protective benefit against the development of gastrointestinal cancers, as shown in a study presented at DDW 2025.